Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Haisco Pharma Licenses Nav1.8 Pain Program to AbbVie in $745M Deal, Retaining Greater China Rights

Fineline Cube Apr 13, 2026
Company Deals

Merck KGaA Closes Acquisition of JSR Life Sciences’ Chromatography Business, Bolstering Antibody Purification Portfolio

Fineline Cube Apr 13, 2026
Company Deals Drug

Boehringer Ingelheim and BioNTech Launch Phase Ib/II Trial of Novel T-Cell Engager and Bispecific Antibody Combo for ES-SCLC

Fineline Cube Apr 13, 2026
Company Deals

Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion, Adding Three First-in-Class Commercial Assets

Fineline Cube Apr 13, 2026
Company Deals

Telix and Regeneron Forge $575M+ Radiopharmaceutical Alliance to Advance Precision Oncology

Fineline Cube Apr 13, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Cutia Therapeutics’ CU-20101 Meets Phase III Endpoints, Demonstrating Non-Inferiority to BOTOX for Glabellar Lines

Fineline Cube Apr 13, 2026
Company Drug

Hotgen Biotech’s Novel Treg-Targeting Bispecific Antibody SGT003 Clears NMPA Filing Hurdle

Fineline Cube Apr 13, 2026
Company Drug

Alphamab Oncology Highlights KN046, KN026 Advances at ESMO 2022

Fineline Cube Sep 5, 2022

China’s Alphamab Oncology (HKG: 9966) will present updated clinical data for its bispecific antibody candidates...

Company Drug

AstraZeneca’s Farxiga Wins China Approval for Chronic Kidney Disease

Fineline Cube Sep 5, 2022

UK pharma giant AstraZeneca (AZ, NASDAQ: AZN) announced a new approval for Farxiga (dapagliflozin), its...

Company Drug

Innovent Biologics Doses First Patient in Higher-Dose Mazdutide Obesity Trial

Fineline Cube Sep 5, 2022

China’s Innovent Biologics, Inc. (HKG: 1801) announced that the first participant has been dosed in...

Company Drug

Shanghai Pharma’s CD20 Antibody Advances to Primary Nephropathy Trial After NMPA Approval

Fineline Cube Sep 5, 2022

China’s Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) has received approval from the National Medical Products...

Company Drug

Walvax Biotech Wins NMPA Approval for mRNA and Recombinant COVID-19 Vaccines

Fineline Cube Sep 2, 2022

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has received clinical trial approvals from the National...

Company Deals

Medim Science Raises Funds for Macrophage-Targeting Biologics in Cancer Therapy

Fineline Cube Sep 2, 2022

Hangzhou-based Medim Science, China’s first pharma firm focused on macrophage-targeting biologics, has reportedly raised tens...

Drug Medical Device

China’s Pharmaceutical Industry Sees Revenue Decline Amid Export Shifts

Fineline Cube Sep 2, 2022

China’s pharmaceutical manufacturing sector reported a 1.8% year-on-year (YOY) revenue decline to RMB 1.6 trillion...

Company Deals

Tibet Duo Rui and Nanjing Heron Forge Pharmaceutical Collaboration in China

Fineline Cube Sep 2, 2022

China-based Tibet Duo Rui Pharmaceutical Co., Ltd and Nanjing Heron Pharmaceutical Science and Technology Co.,...

Company Drug

CARsgen Therapeutics Launches GMP Manufacturing for CAR-T Cell Therapies in North Carolina

Fineline Cube Sep 2, 2022

China’s CARsgen Therapeutics Holdings Ltd (HKG: 2171), a chimeric antigen receptor (CAR)-T cell specialist, has...

Company Deals

MegaRobo and Danaher Life Sciences Partner on Lab Automation in China

Fineline Cube Sep 2, 2022

Beijing-based MegaRobo Technologies, a robotics and AI firm in life sciences, has partnered with Danaher...

Company Drug

Hengrui Medicine’s HRG2101 Inhaler Wins NMPA Approval for IPF Clinical Trial

Fineline Cube Sep 2, 2022

China’s Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has received approval from the National Medical...

Company Deals

U Protech Secures Angel Financing for PROTAC and Molecular Glue Drug Pipeline

Fineline Cube Sep 2, 2022

U Protech, a Hangzhou-based biotech focused on next-generation protein degradation therapies, has raised tens of...

Company Deals Digital

J&J China, Tencent Launch Digital Rhinitis Platform “Love Nose e-Station”

Fineline Cube Sep 2, 2022

Johnson & Johnson’s (J&J, NYSE: JNJ) J&J China Self Care and China’s Tencent have launched...

Company Deals

Neukio Biotherapeutics Completes USD 50M Series A-1 Financing for iPSC-CAR-NK Therapy

Fineline Cube Sep 2, 2022

Shanghai-based Neukio Biotherapeutics, a developer of iPSC-derived chimeric antigen receptor natural killer (CAR-NK) cell therapies,...

Company Deals

Acorda Therapeutics Licenses Preclinical Drug Nepicastat to China’s Asieris

Fineline Cube Sep 2, 2022

US-based Acorda Therapeutics Inc. (Nasdaq: ACOR) announced a licensing agreement with China’s Asieris Pharmaceuticals for...

Policy / Regulatory

SAMR Issues New Rules for Online Drug Sales in China

Fineline Cube Sep 2, 2022

China’s State Administration for Market Regulation (SAMR) has released the “Measures for the Supervision and...

Policy / Regulatory

NMPA Designates Shijiazhuang Airport as Drug Import Port for Narcotics, Psychotropics

Fineline Cube Sep 2, 2022

China’s National Medical Products Administration (NMPA) has designated Shijiazhuang Airport in Hebei Province as an...

Company

Henlius Biotech Plans US Bridging Study for Serplulimab in ES-SCLC

Fineline Cube Sep 1, 2022

Shanghai Henlius Biotech (HKG: 2696) is advancing its checkpoint inhibitor serplulimab toward the U.S. market,...

Company Drug

RedCloud Bio Doses First Patient in H002 EGFR TKI Phase I/IIa Trial for NSCLC

Fineline Cube Sep 1, 2022

Shanghai-based RedCloud Bio announced that the first patient has been dosed in a Phase I/IIa...

Company Drug

Lepu Biopharma’s MRG002 Earns FDA Orphan Drug Status for Gastric Cancer

Fineline Cube Sep 1, 2022

China’s Lepu Biopharma Co., Ltd (HKG: 2157) announced that the U.S. FDA has granted orphan...

Posts pagination

1 … 612 613 614 … 649

Recent updates

  • Cutia Therapeutics’ CU-20101 Meets Phase III Endpoints, Demonstrating Non-Inferiority to BOTOX for Glabellar Lines
  • Hotgen Biotech’s Novel Treg-Targeting Bispecific Antibody SGT003 Clears NMPA Filing Hurdle
  • Haisco Pharma Licenses Nav1.8 Pain Program to AbbVie in $745M Deal, Retaining Greater China Rights
  • FDA Accepts NDA for Telix’s Pixclara (TLX101-Px) Glioma Imaging Agent, Decision Expected September 2026
  • GSK’s B7-H4 ADC Mocertatug Rezetecan Shows 62-67% Response Rates in Phase I Ovarian and Endometrial Cancer Trials
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Cutia Therapeutics’ CU-20101 Meets Phase III Endpoints, Demonstrating Non-Inferiority to BOTOX for Glabellar Lines

Company Drug

Hotgen Biotech’s Novel Treg-Targeting Bispecific Antibody SGT003 Clears NMPA Filing Hurdle

Company Deals

Haisco Pharma Licenses Nav1.8 Pain Program to AbbVie in $745M Deal, Retaining Greater China Rights

Company Drug

FDA Accepts NDA for Telix’s Pixclara (TLX101-Px) Glioma Imaging Agent, Decision Expected September 2026

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.